Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 22,182 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: control 2 Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth

NCT02224625
View directory record Official record
Conditions
Surgery
Interventions
2% CHG Cloth solution, Vehicle Cloth, Active Comparator, Saline, SLS
Drug · Device · Other
Lead sponsor
Medline Industries
Industry
Eligibility
16 Years and older
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Butte, Montana
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 29, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Efficacy in Relieving Dentin Hypersensitivity of Nanohydroxyapatite-Containing Toothpastes and Cream

NCT02918617
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Control toothpaste containing Novamin® technology, Control toothpaste containing 1500 ppm fluoride as MFP, Test toothpaste with nano-HAP (high concentration), Test toothpaste with nano-HAP (low concentration), Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3, Control toothpaste without nano-HAP, Test toothpaste with nano-HAP (medium concentration), Test cream with nano-HAP (higher concentration), Control cream without nano-HAP
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 29, 2026, 2:28 AM EDT
Terminated Phase 3 Interventional

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

NCT05306574
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Telitacicept, Placebo
Biological
Lead sponsor
Vor Biopharma
Industry
Eligibility
12 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Anniston, Alabama • Mission Hills, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 29, 2026, 2:28 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Diabetes in Patients With Systolic Heart Failure

NCT02920918
View directory record Official record
Conditions
Heart Failure, Systolic, Diabetes Mellitus, Type 2
Interventions
Canagliflozin, Sitagliptin
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 29, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

NCT04770220
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
Experimental: ALZ-801, Placebo Comparator: Placebo
Drug
Lead sponsor
Alzheon Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
55
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 29, 2026, 2:28 AM EDT
Terminated Not applicable Interventional

Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma

NCT04123535
View directory record Official record
Conditions
Undifferentiated Pleomorphic Sarcoma
Interventions
ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)
Device
Lead sponsor
Matthew Bucknor
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 29, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

NCT00963508
View directory record Official record
Conditions
Pediculosis
Interventions
Malathion gel 0.5%, Permethrin 1% rinse (Nix Crème)
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Hot Springs, Arkansas • Sacramento, California • Kissimmee, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 29, 2026, 2:28 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

NCT01607450
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Healthy
Interventions
GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose, Saline
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 29, 2026, 2:28 AM EDT
Completed Phase 1 Interventional

To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes

NCT01176097
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD5658, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 29, 2026, 2:28 AM EDT
Completed Not applicable Interventional Results available

Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC): Reducing Tobacco Use Among Opioid Addicted Women

NCT03796208
View directory record Official record
Conditions
Smoking Cessation
Interventions
Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC), Treatment As Usual
Behavioral
Lead sponsor
Kristin Ashford
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 29, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

Naproxen Sodium/Acetaminophen Proof of Concept Dosing Study

NCT03879408
View directory record Official record
Conditions
Pain
Interventions
440 mg naproxen sodium with 1000 mg acetaminophen, 220 mg naproxen sodium with 650 mg acetaminophen, 10 mg hydrocodone + 650 mg acetaminophen, 440 mg naproxen sodium, Placebo tablet
Drug
Lead sponsor
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Industry
Eligibility
17 Years to 50 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 29, 2026, 2:28 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

NCT04639050
View directory record Official record
Conditions
Alzheimers Disease
Interventions
RO7126209, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
15
States / cities
Atlantis, Florida • Clermont, Florida • Lady Lake, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 29, 2026, 2:28 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

NCT07654374
View directory record Official record
Conditions
Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
Interventions
aleniglipron, Placebo
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
74
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 29, 2026, 2:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Addressing Health Literacy and Numeracy to Prevent Childhood Obesity

NCT01040897
View directory record Official record
Conditions
Obesity Prevention
Interventions
Health Communication and Obesity Prevention, Injury Prevention Arm
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
6 Weeks to 12 Weeks
Enrollment
865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 29, 2026, 2:28 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Tribally Engaged Approaches to Lung Screening (TEALS)

NCT04948060
View directory record Official record
Conditions
Lung Cancer
Interventions
Enhanced lung cancer screening services
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
50 Years to 80 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 29, 2026, 2:28 AM EDT
Recruiting Not applicable Interventional

A Pilot of a Personalized Circadian mHealth to Improve Sleep in Night Shift Workers

NCT06809335
View directory record Official record
Conditions
Shift Work Sleep Disorder
Interventions
Personalized circadian mHealth
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Novi, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 29, 2026, 2:28 AM EDT
Completed Phase 2Phase 3 Interventional

A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome

NCT05163808
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
zatolmilast, Placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
9 Years to 18 Years · Male only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Irvine, California • Orange, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 29, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

NCT01024608
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Hay Fever
Interventions
Beclomethasone dipropionate, Placebo Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 29, 2026, 2:28 AM EDT
Terminated Phase 3 Interventional Results available

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

NCT01975376
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
bococizumab (PF-04950615), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
545
States / cities
Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 339 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 29, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

NCT01395017
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
dasatinib, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 29, 2026, 2:28 AM EDT
Completed Phase 2 Interventional Results available

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

NCT03428217
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
CB-839, Cabozantinib, Placebo
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 29, 2026, 2:28 AM EDT
Completed Phase 2 Interventional

A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

NCT01507168
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Placebo, GC33
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
Los Angeles, California • Bethesda, Maryland • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 29, 2026, 2:28 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

NCT03358290
View directory record Official record
Conditions
Plaque Psoriasis, Skin Diseases
Interventions
JTE-051, Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Fountain Valley, California • Fremont, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 29, 2026, 2:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of NRS 033 in Healthy Volunteers

NCT05724797
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NRS-033, Placebo
Drug
Lead sponsor
Nirsum Labs
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 29, 2026, 2:28 AM EDT